| Literature DB >> 27108295 |
Leonie A Tepper1,2, Daan Caudri1, Adria Perez Rovira1,3, Harm A W M Tiddens4,5,6, Marleen de Bruijne3,7.
Abstract
OBJECTIVE: Bronchiectasis is an important component of cystic fibrosis (CF) lung disease but little is known about its development. We aimed to study the development of bronchiectasis and identify determinants for rapid progression of bronchiectasis on chest CT.Entities:
Keywords: Bronchiectasis; Cystic fibrosis; High resolution computed tomography; Lung disease; Paediatrics
Mesh:
Year: 2016 PMID: 27108295 PMCID: PMC5101271 DOI: 10.1007/s00330-016-4329-z
Source DB: PubMed Journal: Eur Radiol ISSN: 0938-7994 Impact factor: 5.315
Fig. 1Illustration of scoring categories: bronchiectasis (left), mucus plugging (middle) and airway wall thickening (right)
Fig. 2Flowchart of the study population. CF cystic fibrosis, ROIs regions of interest
Baseline characteristics of the study cohort
| Characteristic | CTbaseline | CTminus 2 | CTminus 4 | CTminus 6 | CTminus 8 |
|---|---|---|---|---|---|
| Number of patients | 43 | 43 | 43 | 43 | 4 |
| Number of regions of interest | 367 | 367 | 367 | 367 | 46 |
| Gender (males) | 18 (41.9) | 18 (41.9) | 18 (41.9) | 18 (41.9) | 3 (75.0) |
| Age, year | 15.3 (9–24) | 13.2 (6–22) | 11.0 (4–18) | 9.0 (2–16) | 6.8 (2–10) |
| SES# | |||||
| Low | 12 (29.3) | 12 (29.3) | 12 (29.3) | 12 (29.3) | 1 (25.0) |
| Average | 15 (36.6) | 15 (36.6) | 15 (36.6) | 15 (36.6) | 1 (25.0) |
| High | 13 (31.7) | 13 (31.7) | 13 (31.7) | 13 (31.7) | 2 (50.0) |
| Scientific | 1 (2.4) | 1 (2.4) | 1 (2.4) | 1 (2.4) | 0 (0.0) |
| Genetics | |||||
| Homozygous dF508 | 30 (69.8) | 30 (69.8) | 30 (69.8) | 30 (69.8) | 3 (75.0) |
| Heterozygous dF508 | 9 (20.9) | 9 (20.9) | 9 (20.9) | 9 (20.9) | 1 (25.0) |
| Heterozygous other mutation | 4 (9.3) | 4 (9.3) | 4 (9.3) | 4 (9.3) | 0 (0.0) |
| Presence of co-morbidities‡ | |||||
| Pancreatic insufficient | 40 (93.0) | 40 (93.0) | 40 (93.0) | 40 (93.0) | 3 (75.0) |
| CFRD | 10 (23.3) | 10 (23.3) | 10 (23.3) | 10 (23.3) | 0 (0.0) |
| Asthma | 3 (7.0) | 3 (7.0) | 3 (7.0) | 3 (7.0) | 0 (0.0) |
| ABPA | 2 (4.7) | 2 (4.7) | 2 (4.7) | 2 (4.7) | 0 (0.0) |
| Chronic colonization | 8 (18.6) | 8 (18.6) | 8 (18.6) | 8 (18.6) | 1 (25.0) |
| BMI | 19.2 (15–36) | 18.0 (14–30) | 17.0 (5–31) | 16.5 (14–25) | 15.7 (15–17) |
| FEV1, % predicted | 86.5 (33–106) | 85.4 (37–112) | 85.0 (40–113) | 85.8 (42–126) | 88.4 (85–92) |
| FVC, % predicted | 94.0 (49–115) | 92.3 (56–128) | 95.2 (57–118) | 93.2 (49–128) | 99.0 (94–102) |
Data are presented as no. (%) or median (range)
CTbaseline– minus8 indicate the time points at which the CTs were made, with CTbaseline representing the most recent CT and CTminus2-8 respectively representing the CT made 2, 4, 6 or 8 years before CTbaseline
# SES: socio-economic status based on the highest level of education of either parent (n = 41 at CTbaseline– minus6 and n = 4 at CTminus 8)
‡ Indicating the number of patients having co-morbidities
‡ ‡ Chronic colonization Pa: defined as ≥ three consecutive positive respiratory cultures for Pseudomonas aeruginosa (Pa) from birth to CTbaseline
CFRD CF-related diabetes, ABPA allergic bronchopulmonary aspergillosis, BMI body mass index, FEV forced expiratory volume in 1 s, FVC forced vital capacity
Fig. 3Structural lung damage over time (n = 362 in 43 patients). Dark grey represents bronchiectasis, light-dark grey (area above dark grey) represents mucus plugging, grey dots represent airway wall thickening, white dots represent atelectasis/consolidation, light grey (on top) represents normal airways. CTbaseline is the most recent CT